Zydus Cadila receives final approval from the USFDA for Cisatracurium Besylate Injection

Zydus Cadila has received final approval from the USFDA to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.

Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration. It is an adjunct to general anaesthesia to facilitate tracheal intubation in adults and in paediatric patients 1 month to 12 years of age and to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU. The drug will be manufactured at Liva plant of Cadila Healthcare Limited.

The group now has 297 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.379.25 as compared to the previous close of Rs. 371.1. The total number of shares traded during the day was 104287 in over 1860 trades.

The stock hit an intraday high of Rs. 379.25 and intraday low of 366.8. The net turnover during the day was Rs. 38941050.

Source : Equity Bulls

Keywords